Ammonia Solution, Strong

Ammonia Solution, Strong

SCHEMBL6000870

CCC(c1cccc(F)c1)c1ccccc1C.N

nearest known ligand 0.49

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 1/20 0.41
TDO2 P48775 1/20 0.41
SLC6A4 P31645 4/20 0.40
SLC6A2 P23975 3/20 0.40
CYP2D6 P10635 2/20 0.40
SLC22A2 O15244 1/20 0.40
SLC22A1 O15245 1/20 0.40
GRIN2D O15399 1/20 0.40
GRIN3B O60391 1/20 0.40
CHRM2 P08172 1/20 0.40
CHRM4 P08173 1/20 0.40
CHRM5 P08912 1/20 0.40
ADRA2A P08913 1/20 0.40
CHRM1 P11229 1/20 0.40
ADRA2B P18089 1/20 0.40
CHRM3 P20309 1/20 0.40
DRD1 P21728 1/20 0.40
HRH2 P25021 1/20 0.40
HTR2A P28223 1/20 0.40
HTR2C P28335 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ammonia Solution, Strong SCHEMBL5999547 0.87 IDO1 (0.38) IDO1TDO2SLC6A4SLC6A2CNR2
Ammonia Solution, Strong SCHEMBL6001224 0.85 IDO1 (0.42) IDO1TDO2SLC6A4SLC6A2CNR2
Ammonia Solution, Strong SCHEMBL5999540 0.84 IDO1 (0.47) IDO1TDO2SLC6A4SLC6A2HTR2A
Ammonia Solution, Strong SCHEMBL6001307 0.84 IDO1 (0.46) IDO1TDO2SLC6A4SLC6A2CNR2
SCHEMBL6000867 0.83 HRH1 (0.44) IDO1TDO2SLC6A4SLC6A2HRH1
SCHEMBL23126406 0.83 IDO1 (0.49) IDO1TDO2SLC6A4SLC6A2HTR2A
Ammonia Solution, Strong SCHEMBL6000543 0.83 BCHE (0.48) IDO1TDO2SLC6A4SLC6A2CYP2C19
Ammonia Solution, Strong SCHEMBL6001280 0.83 IDO1 (0.37) IDO1TDO2SLC6A4SLC6A2CNR2
SCHEMBL22048343 0.82 IDO1 (0.47) IDO1TDO2SLC6A4SLC6A2CNR2
Ammonia Solution, Strong SCHEMBL5999526 0.81 BCHE (0.50) IDO1TDO2SLC6A4SLC6A2SLC6A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060142594-A1 Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases MUELLER ALAN L 2006-06-29 US disclosed
US-6750244-B2 NERVOUS SYSTEM DISORDERS NPS PHARMACEUTICALS, INC. 2004-06-15 US disclosed
US-6211245-B1 DRUGS FOR CONTROLLING CALCIUM MODULATORS NPS PHARMACEUTICALS, INC. 2001-04-03 US disclosed
US-6051610-A COMPOUNDS USEFUL AS NEUROPROTECTANTS, ANTICONVULSANTS, ANXIOLYTICS, ANALGESICS, MUSCLE RELAXANTS OR ADJUVANTS TO GENERAL ANESTHETICS NPS PHARMACEUTICALS, INC. (US) 2000-04-18 US disclosed
US-6017965-A TREATING STROKE, HEAD TRAUMA, SPINAL CORD INJURY, SPINAL CORD ISCHEMIA, ISCHEMIA- OR HYPOXIA-INDUCED NERVE CELL DAMAGE, EPILEPSY, ANXIETY, NEUROPSYCHIATRIC OR COGNITIVE DEFICITS DUE TO ISCHEMIA OR HYPOXIA NPS PHARMACEUTICALS, INC. (US) 2000-01-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060142594-A1 Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases NCS1, ATP2A1, CACNA1D IDO1 3661/4885TDO2 3085/4885SLC6A4 1786/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.